botensilimab,balstilimab
agenus
bot/bal delivered a 24% orr (10/41 patients), 73% disease control rate (partial response + stable disease), and median dor was not reached. 80% of objective responses were ongoing at data cut-off, and 30% of objective responses exceeded 1 year. #esmogi
Our goal is to treat cancers with novel combinations using our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines & adjuvants